| Literature DB >> 36105393 |
Yulia Gennadevna Samoilova1, Mariia Vladimirovna Matveeva1, Olga Sergeevna Tonkih2, Dmitry Anatolievich Kudlay3, Oxana Alekseevna Oleynik1, Stephen Olaide Aremu1, Oksana Yurievna Kilina4, Alexander Federovich Kanev5, Olga Mihailovna Gerget6.
Abstract
With an ageing of population and a splurging epidemic of diabetes mellitus (DM), the prevalence of complications associated with pathology of the central nervous system are expected to increase, which in the future may have serious consequences for public health. It is known that one of the main manifestations of brain damage in type 1 diabetes is cognitive impairment, which is possibly associated with the peculiarities of vascularization and interhemispheric asymmetry, which requires in-depth analysis using modern neuroimaging methods. The aim of the study is to assess the symmetry of structural, metabolic and neurovascularization changes in the brain in patients with type 1 diabetes and cognitive impairment. The study included 120 patients with type 1 diabetes aged 18 to 45 years suffering from cognitive impairment, and 30 people without cognitive decline and the control group (n=30) healthy people without diabetes. Neuropsychological testing included the Montreal Cognitive Dysfunction Assessment Scale (MoCA test). For neuroimaging methods, standard magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), contrast and non-contrast-enhanced perfusion were used. Statistical processing was carried out using the SPSS Statistic 2020 software. In patients with type 1 diabetes with cognitive impairment, as manifested by impaired memory and/or attention, perfusion imaging revealed the presence of brain asymmetry zones. Standard MRI allowed to demonstrate changes in the white, gray matter and hippocampus in the right hemisphere. The results obtained were refined taking into account the topical localization, so during the perfusion study, regions with asymmetric blood flow were identified - namely, the white matter of the frontal lobe and the gray matter in the occipital lobe. Spectroscopy of the brain revealed that it was in these areas of the brain that the most significant metabolic disorders were noted - in the form of significantly altered ratio of N-acetylaspartate (NAA)/choline (Cho) on the left, along with the asymmetry in phosphocreatine level (Cr 2) on the right. In conclusion, early preclinical predictive diagnostics with the use of modern neuroimaging methods allows for timely detection of impaired vascularization and brain metabolism in this group of patients, However, decreased perfusion in the region within the region of frontal lobe white matter and temporal lobe grey matter, and hippocampal cell metabolism by spectra should be highlighted among the parameters Cr right and NAA/Cho left.Entities:
Keywords: brain; cognitive impairment; interhemispheric asymmetry; neuroimaging; type 1 diabetes mellitus
Mesh:
Substances:
Year: 2022 PMID: 36105393 PMCID: PMC9465454 DOI: 10.3389/fendo.2022.961254
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Characteristics of patients with type 1 DM (Me [Q1; Q3]).
| Parameters | Patients with type 1 DM and cognitive impairment, n = 120 | Patients with type 1 DM without cognitive impairment, n = 30 | Patients without DM, n = 30 |
|
|---|---|---|---|---|
| Age, years | 27[18:45] | 26 [23:39] | 27 [23:39] | 0,2 |
| Disease duration, years | 11 [1:32] | 13 [2:24] | – | 0,2 |
| Fasting plasma glucose, mmol/l | 9.1 [6.4:16.4] | 7,9 [5.5:18.3] | 4,9 [3.8:5.3] | 0,05 |
| HbA1c,% | 7.6 [6:12.4] | 6.9 [4.5:10.3] | 4.9 [3.8:5.8] | 0,2 |
| Body weight index, kg/m2 | 22.6 [17.4:30.6] | 21.8 [16:30.4] | 21.7 [18:29.3] | 0,2 |
p ≤ 0,05 – significant differences.
Characteristics of patient groups according to the presence of microvascular complications of type 1 DM.
| Complications | Patients with type 1 DM and cognitive impairment, n = 120 | Patients with type 1 DM without cognitive impairment, n = 30 |
|
|---|---|---|---|
| Angioretinopathy,% | 75% | 63,3% | 0,045 |
| Polyneuropathy,% | 62,4% | 70% | 0,359 |
| Nephropathy, % | 45,8 | 20% | 0,025 |
p ≤ 0,05 – significant differences.
Brain segmentation in patients with type 1 DM.
| Anatomic region | Patients with type 1 DM, n = 150 | Patients without DM, n = 30 |
| |
|---|---|---|---|---|
| With cognitive impairment, n = 120 | Without cognitive impairment, n = 30 | |||
| Grey matter, mm3 | 478009 | 497704 | 626496 [593716; 649388] | 0,106 |
| Grey matter, left hemisphere, mm3 | 225046 | 252441 | 295734 [278564; 301837] | 0,0004 |
| Gray matter, right hemisphere, mm3 | 235085 | 253587 | 298546 [278058;320759] | 0,015 |
| White matter, mm3 | 455968 | 503517 [440036,6- 509720,7] | 659724 [6391765;689266] | 0,005 |
| White matter, left hemisphere, mm3 | 232213 | 241831 [217516,8-264238,8] | 359624 [338616;378166] | 0,639 |
| White matter, right hemisphere, mm3 | 235509 | 270207 | 365926 [329764;387165] | 0,046 |
| Left hippocampus, mm3 | 73 [72,1-73,4] | 73 [72,9-74,8] | 77,8 [76,8;79,2] | 0,141 |
| Right hippocampus, mm3 | 72 [71,1-73,2] | 73 [72,4-75,0] | 78,3 [76,3;79] | 0,005 |
p ≤ 0,05 – significant differences.
Figure 1An image depicting an example of asymmetry perfusion in patent with diabetes type 1.
Asymmetry of neurovascularization according to contrast and non-contrast perfusion in patients with type 1 diabetes mellitus and cognitive impairment.
| Localization and indices of perfusion | U-statistics | P value |
|---|---|---|
| Frontal lobe, white matter, MTT/sec | 201,5000 | 0,032032 |
| Temporal lobe, grey matter, ASL/CBF | 201,5000 | 0,032032 |
U-Mann-Whitney test, p-value ≤ 0.05; MTT, mean transit time; AS, arterial spin labeling - method of spin labeling of arterial blood; CBF, cerebral blood flow.
Correlation matrix for checking the normality of parameters of proton spectroscopy of the brain.
| NAA left | NAA right | Cho left | Cho right | Cr left | Cr right | Cr2 left | Cr2 right | NAA/Cr left | NAA/Cr right | NAA/Cho left | NAA/Cho right | Cho/Cr left | Cho/Cr right | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NAA left | 1 | 0,5 | 0,01 | -0,9 | 0,2 | 0,3 | 0,3 | 0,4 | -0,1 | 0,02 | -0,5 | -0,2 | -0,1 | -0,4 |
| NAA right | 0,5 | 1 | 0,22 | 0,2 | 0,3 | 0,3 | 0,6 | 0,4 | 0,1 | 0,2 | -0,3 | -0,4 | -0,0 | -0,4 |
| Cho left | 0,01 | 0,22 | 1 | 0,4 | 0,2 | 0,4 | 0,1 | 0,1 | 0,7 | 0,7 | 0,4 | 0,2 | 0,6 | -0,2 |
| Cho right | -0,9 | 0,2 | 0,4 | 1 | -0 | -0 | 0,1 | -0,1 | 0.1 | 0,1 | 0 | 0,1 | 0,45 | 0,4 |
| Cr left | 0,2 | 0,3 | 0,2 | -0 | 1 | 0,3 | 0,1 | 0,2 | 0,3 | 0,1 | -0 | 0 | -0,3 | -2,3 |
| Cr right | 0,3 | 0,3 | 0,4 | -0 | 0,3 | 1 | 0,1 | 0,4 | 0,6 | 0,6 | 0,1 | 0,2 | 0,1 | -0,5 |
| Cr2 left | 0,3 | 0,6 | 0,1 | 0,1 | 0,1 | 0,1 | 1 | 0,5 | -0,1 | 0 | -0,4 | -0,4 | 0 | -0,3 |
| Cr2 right | 0,4 | 0,4 | 0,1 | -0,1 | 0,2 | 0,4 | 0,5 | 1 | 0,16 | 0,15 | -0,1 | -0,1 | 0 | -0,3 |
| NAA/Cr left | -0,1 | 0,1 | 0,7 | 0,1 | 0,3 | 0,6 | -0,1 | 0,16 | 1 | 0,8 | 0,65 | 0,4 | 0,4 | -0,2 |
| NAA/Cr right | 0,02 | 0,2 | 0,7 | 0,3 | 0,1 | 0,6 | 0 | 0,15 | 0,8 | 1 | 0,35 | 0,47 | 0,6 | -0,3 |
| NAA/Cho left | -0,5 | -0,3 | 0,4 | 0 | -0 | 0,1 | -0,4 | -0,1 | 0,65 | 0,35 | 1 | 0,5 | 0,2 | 0,3 |
| NAA/Cho right | -0,2 | -0,4 | 0,2 | 0,1 | 0 | 0,2 | -0,4 | -0,1 | 0,4 | 0,47 | 0,5 | 1 | 0,2 | 0,4 |
| Cho/Cr left | -0,1 | -0,0 | 0,6 | 0,45 | -0,3 | 0,1 | 0 | 0 | 0,4 | 0,6 | 0,2 | 0,2 | 1 | 0,1 |
| Cho/Cr right | -0,4 | -0,4 | -0,2 | 0,4 | -2,3 | -0,5 | -0,3 | -0,3 | -0,2 | -0,3 | 0,3 | 0,4 | 0,1 | 1 |
NAA, N-acetylaspartate; Cho, choline; Cr, creatine; Cr2, phosphocreatine.
Values of the Kruskal-Wallis rank test for parameters of proton spectroscopy of the brain of patients with type 1 diabetes mellitus.
| Parameter | Statistics | p-value |
|---|---|---|
|
| 22,62228 | 0,0001 |
|
| 26,53589 | 0,0003 |
|
| 28,52084 | 0,0000 |
|
| 14,18308 | 0,0027 |
|
| 5,721290 | 0,1260 |
|
| 33,81858 | 0,0000 |
|
| 29,96852 | 0,0002 |
|
| 34,03594 | 0,0001 |
|
| 33,19992 | 0,0000 |
|
| 31,45471 | 0,0001 |
|
| 34,10368 | 0,0004 |
|
| 33,72973 | 0,0001 |
|
| 23,58656 | 0,0000 |
|
| 18,70439 | 0,0003 |
NAA, N-acetylaspartate; Cho, choline; Cr, creatine; Cr2, phosphocreatine.
Figure 2Diagram showing the significance of MRS parameters highlighting the importance of features. * - statistical significance (p ≤ 0,05).